Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis

APMIS

Volumn 115, Issue 1, 2007, Pages 30-46

  Bahramsoltani, Mahtab ^a   Plendl, Johanna ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Angiogenesis; Angiostatic factors; Antiangiogenesis; In vitro; Quantitation

Indexed keywords

ANGIOSTATIN; SURAMIN;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; IN VITRO STUDY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTINEOPLASTIC AGENTS; ENDOTHELIUM, VASCULAR; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SURAMIN;

EID: 33846120511     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2007.apm_405.x     Document Type: Article

References (86)

1. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003;(Suppl):S127-33.
2. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
3. Plendl J, Gilligan BJ, Wang SJ, Lewis R, Shiners B, Vandenbroeck K, et al. Primitive endothelial cell lines from the porcine embryonic yolk sac. In Vitro Cell Dev Biol Anim 2002;38:334-42.
4. Plendl J. Angiogenesis in the bovine ovary. A review. Anat Histol Embryol 2000;29:257-66.
5. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003;22:6549-56.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-32.
7. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005;6:511-24.
8. Banning M. The principles of inflammation in the development of rheumatoid arthritis. Br J Nurs 2005;14:277-83.
9. Gowda RM, Khan IA, Punukollu G, Vasavada BC, Nair CK. Treatment of refractory angina pectoris. Int J Cardiol 2005;101:1-7.
10. Markkanen JE, Rissanen TT, Kivela A, Yla-Herttuala S. Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart - gene therapy. Cardiovasc Res 2005;65:656-64.
11. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-55.
12. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of angiostatic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23:1295-311.
13. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene 2003;22:6537-48.
14. Haas TL. Endothelial cell regulation of matrix metalloproteinases. Can J Physiol Pharmacol 2005;83:1-7.
15. Ribatti D, Ponzoni M. Angiostatic strategies in neuroblastoma. Cancer Treat Rev 2005;31:27-34.
16. Manson MM, Farmer PB, Gescher A, Steward WP. Innovative agents in cancer prevention. Recent Results Cancer Res 2005;166:257-75.
17. Folkman J, Haudenschild C. Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc UK 1980;100:346-53.
18. Vailhé B, Vittet D, Feige JJ. In vitro models of vasculogenesis and angiogenesis. Lab Invest 2001;81:439-52.
19. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983;97:1648-52.
20. Nehls V, Drenckhahn D. A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 1995;50:311-22.
21. Hoying JB, Williams SK. Measurement of endothelial cell migration using an improved linear migration assay. Microcirculation 1996;3:167-74.
22. Meyer GT, Matthias LJ, Noack L, Vadas MA, Gamble JR. Lumen formation during angiogenesis in vitro involves phagocytic activity, formation and secretion of vacuoles, cell death, and capillary tube remodelling by different populations of endothelial cells. Anat Rec 1997;249:327-40.
23. Peters K, Schmidt H, Unger RE, Otto M, Kamp G, Kirkpatrick J. Software-supported image quantification of angiogenesis in an in vitro culture system: application to studies of biocompatibility. Biomaterials 2002;23:3413-19.
24. Rookmaaker MB, Verhaar MC, Loomans CJ, Verloop R, Peters E, Westerweel PE, et al. CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD34- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol 2005;25:1843-50.
25. Wang H, Riha GM, Yan S, Li M, Chai H, Yang H, et al. Shear stress induces endothelial differentiation from a murine embryonic mesenchymal progenitor cell line. Arterioscler Thromb Vasc Biol 2005;25:1817-23.
26. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 2005;280:27138-46.
27. Montanez E, Casaroli-Marano RP, Vilaro S, Pagan R. Comparative study of tube assembly in three-dimensional collagen matrix and on Matrigel coats. Angiogenesis 2002;5:167-72.
28. Bahramsoltani M, Plendl J. A new in vitro model to quantify angiogenesis. ALTEX 2004;21:227-44.
29. Lienau J, Kaletta C, Teifel M, Naujoks K, Bhoola K, Plendl J. Morphology and transfection study of human microvascular endothelial cell angiogenesis: an in vitro three-dimensional model. Biol Chem 2005;386:167-75.
30. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496-507.
31. te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF, et al. Adverse effects of the angiostatic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 2002;9:303-9.
32. de Castro Junior G, Puglisi F, de Azambuja E, El Saghir NS, Awada A. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm). Crit Rev Oncol Hematol 2006;59:40-50.
33. Ren B, Hoti N, Rabasseda X, Wang YZ, Wu M. The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003;25:215-24.
34. Kurup A, Lin CW, Murry DJ, Dobrolecki L, Estes D, Yiannoutsos CT, et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006;17:97-103.
35. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003;21:2299-304.
36. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R. Neovastat - a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 2003;14:91-6.
37. Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis assays: a critical overview. Clin Chem 2003;49:32-40.
38. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
39. Barendsz-Janson AF, Griffioen AW, Muller AD, van Dam-Mieras MCE, Hillen HFP. In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 inhibits in vitro tumor-induced angiogenesis. J Vasc Res 1998;35:109-14.
40. Griscelli F, Hong L, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998;95:6367-72.
41. Beecken WD, Engl T, Blaheta R, Bentas W, Achilles EG, Jonas D, et al. Angiogenesis inhibition by angiostatin, endostatin and TNP-470 prevents cyclophosphamide induced cystitis. Angiogenesis 2004;7:69-73.
42. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004;5:485-93.
43. Lainer DT, Brahn E. New angiostatic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drug 2005;14:1-17.
44. Larsen AK. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol 1993;32:96-8.
45. Bernsen HJ, Rijken PF, Peters JP, Bakker JH, Boerman RH, Wesseling P, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 1999;44:129-36.
46. Bocci G, Danesi R, Benelli U, Innocenti F, Di Paolo A, Fogli S, et al. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 1999;43:205-12.
47. Meyers MO, Gagliardi AR, Flattmann GJ, Su JL, Wang YZ, Woltering EA. Suramin analogs inhibit human angiogenesis in vitro. J Surg Res 2000;91:130-4.
48. Berger AC, Wang XQ, Zalatoris A, Cenna J, Watson JC. A murine model of ex vivo angiogenesis using aortic discs grown in fibrin clot. Microvasc Res 2004;68:179-87.
49. Ganesh VK, Muthuvel SK, Smith SA,Kotwal GJ, Murthy KH. Structural basis for antagonism by suramin of heparin binding to vaccinia complement protein. Biochemistry 2005;44:10757-65.
50. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cell in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro. Arteriosc Thromb Vasc Biol 1999;19:2041-8.
51. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001;98:6656-61.
52. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998;95:5579-83.
53. Chavakis E, Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler Thromb Vasc Biol 2002;22:887-93.
54. Ito H, Rovira II, Bloom ML, Takeda K, Ferrans VJ, Quyyumi AA. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999;59:5875-7.
55. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999;340:77-84.
56. Hawking F. Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother 1978;15:289-322.
57. Nok AJ. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol Res 2003;90:71-9.
58. Gagliardi A, Hadd H, Collins DC. Inhibition of angiogenesis by suramin. Cancer Res 1992;52:5073-5.
59. Zogakis TG, Libutti SK. General aspects of antiangiogenesis and cancer therapy. Expert Opin Biol Ther 2001;1:253-75.
60. Laterra JJ, Grossman SA, Carson KA, Lesser GJ, Hochberg FH, Gilbert MR. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neurooncol 2004;6:15-20.
61. Nash P, Wentzel P, Lindeberg S, Naessen T, Jansson L, Olovsson M, et al. Placental dysfunction in Suramin-treated rats - a new model for preeclampsia. Placenta 2005;26:410-8.
62. Niemisto A, Dunmire V, Yli-Harja O, Zhang W, Shmulevich I. Robust quantification of in vitro angiogenesis through image analysis. IEEE Trans Med Imaging 2005;24:549-53.
63. Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 2003;104:167-74.
64. Plendl J, Neumüller C, Sinowatz F. Differences of microvascular endothelium in the bovine corpus luteum of pregnancy and the corpus luteum of the estrous cycle. Biol Cell 1996;87:179-88.
65. Plendl J, Neumüller C, Vollmar A, Auerbach R, Sinowatz F. Isolation and characterization of endothelial cells from different organs of fetal pigs. Anat Histol Embryol 1996;194:445-56.
66. Plendl J. Angiogenesis and vascular regression in the ovary. Anat Histol Embryol 2000;29:257-66.
67. Plendl J, Snyman C, Bhoola K. Expression of tissue kininogenase in the granulosa cells of the ovary. Biol Chem 2002;383:1917-24.
68. Plendl J, Snyman C, Bhoola KD. Visualization of the sequential changes in immunolabelled tissue kininogenase which accompany follicular development and luteinization of angiogenic granulosa cells of the ovary. Int Immunopharmacol 2002;2:1981-94.
69. Folkman J, Haudenschild C, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci USA 1979;76:5217-21.
70. Peverali FA, Mandriota SJ, Ciana P, Marelli R, Quax P, Rifkin DB, et al. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J Cell Physiol 1994;161:1-14.
71. Iwahana M, Nakayama Y, Tanaka NG, Groyo M, Okada K. Quantification of tumour-induced angiogenesis by image analysis. Int J Exp Pathol 1996;77:109-14.
72. Seghezzi G, Marelli R, Mandriota SJ, Nolli ML, Mazzieri R, Mignatti P. Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. J Cell Physiol 1996;169:300-8.
73. Kruger EA, Figg WD. Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay. Clin Cancer Res 2001;7:1867-72.
74. Sachs L. Statistische Tests: Standardtests. In: Sachs L, editor. Statistische Methoden, Berlin, Heidelberg, New York: Springer-Verlag, 1993.
75. Bahramsoltani M. Quantitation of angiogenesis and antiangiogenesis in vitro. Dissertation thesis. Faculty of Veterinary Anatomy, Freie Universität Berlin, 2004. http://www.diss.fu-berlin.de/2004/110/
76. Hirschberg RM, Sachtleben M, Plendl J. Electron microscopy of cultured angiogenic endothelial cells. Microsc Res Tech 2005;67:248-59.
77. Dye J, Lawrence L, Linge C, Leach L, Firth J, Clark P. Distinct patterns of microvascular endothelial cell morphology are determined by extracellular matrix composition. Endothelium 2004;11:151-67.
78. 3 in endothelial cells. J Biol Chem 2001;276:39562-8.
79. Distler JW, Hirth A, Kurovska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med 2005;47:149-61.
80. Chen YH, Wu HL, Li C, Huang YH, Chiang CW, Wu MP, et al. Anti-angiogenesis mediated by angiostatin K1-3, K1-4 and K1-4.5. Involvement of p53, FasL, AKT and mRNA deregulation. Thromb Haemost 2006;95:668-77.
81. Urasawa K, Kaneta S, Nakano N, Saito T, Sakai H, Takagi C, et al. Vascular smooth muscle cell proliferation is effectively suppressed by the non-specific growth factor inhibitor suramin. Jpn Heart J 2001;42:221-33.
82. Firsching-Hauck A, Nickel P, Yahya C, Wandt C, Kulik R, Simon N, et al. Angiostatic effects of suramin analogs in vitro. Anticancer Drugs 2000;11:69-77.
83. Langer I, Atassi G, Robberecht P, Resibois A. Eriochrome Black T inhibits endothelial cell growth through S-phase blockade. Eur J Pharmacol 2000;399:85-90.
84. Huber D, Cramer EM, Kaufmann JE, Meda P, Masse JM, Kruithof EK, et al. Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002;99:3637-45.
85. Lucas R, Holmgren L, Gracia I, Jimenez B, Mandriota SJ, Borlat F, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-41.
86. Veitonmaki N, Cao R, Wu LH, Moser TL, Li B, Pizzo SV, et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced antiangiogenesis. Cancer Res 2004;64:3679-86.